β-lactamase inhibitor and process for preparing the same

US9708320B2 · kind B2 · utility

Assignee

• MEIJI SEIKA PHARMA CO., LTD. · JP

Inventors

• Takao Abe · Yokohama, JP
• Takeshi Furuuchi · Yokohama, JP
• Yoshiaki Sakamaki · Yokohama, JP
• Seiichi Inamura · Yokohama, JP
• Akihiro Morinaka · Yokohama, JP

Key dates

• Filing date: Oct 1, 2015
• Grant date: Jul 18, 2017
• Expiry date: Oct 1, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I):wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC1-6 alkyl; C represents benzyl, H or SO3M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C1-6 alkyl or acyl; Rc represents C1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C1-6 alkyl, O═, or Rg-(CH2)0-3—, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO2S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C1-6 alkyl or MO—; Re and Rf represent H or C1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.